DocMorris AG (0RRB) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everybody. And thank you for joining today's conference call, which will be hosted by Daniel Wurst, our CFO and me. Let me start by giving you a quick overview of the key highlights from the first half of 2025. We delivered strong growth in our RX business, with revenue increased by 43.5%. In July, The RX bonus was reconfirmed, which strengthens our competitive positioning in the German market. Teleclinic revenue grew by more than 150% year-on-year, while our non-RX business in total continued to deliver steady and profitable growth of 4.4%. We also took an important step into the future by leveraging AI innovation and starting the rollout of the DocMorris Health Companion. Financially, we successfully completed the 200 million CHF capital increase with a 99% take-up rate, demonstrating strong shareholder support and confidence in our strategy. And finally, we are on track to deliver on our promises. We confirm our guidance of more than 10% revenue growth and an EBITDA in the range of minus 35 to minus 55 million Swiss francs for the full year. In summary, the first half of 25 shows clearly our core business is growing steadily, our new value drivers are scaling fast, and we are well funded and on track to deliver on our commitments. Let's start with the ecosystem highlights on slide number five. And let me walk through how our company is evolving from yesterday to today and to tomorrow. Yesterday, our focus was on building and strengthening a leading online pharmacy in Germany and across Europe. We became the best-known pharmacy brand in the market and are best positioned and strongly accelerating our growth in the 58 billion euro Rx market in Germany. At the same time, we built a profitable non-Rx business. This gave us not only scale, but also the tr...